Xiaoli Zhang, Xue Meng, Hui Zhu, Qiuan Yang, K. Morris, Terence Herman, Jinming Yu, Min Li
Pancreatic cancer (PC) is one of the leading causes of cancer death worldwide. Limited therapeutic options are available. Therefore, how to detect early-stage tumors and how to monitor treatment efficacy and outcomes to allow timely salvage therapies are of crucial importance. Position emission tomography (PET) imaging provides more tumor-associated functional, biochemical and molecular information, without some of the intrinsic limitations of traditional imaging modalities. PET is highlighted as a potential tool to help better understand the mechanism of PC and personalize individual therapeutic regimens. In this review, we outline the available PET imaging modalities and their prospective applications in PC.
{"title":"Position emission tomography imaging in pancreatic cancer: recent progress and future directions","authors":"Xiaoli Zhang, Xue Meng, Hui Zhu, Qiuan Yang, K. Morris, Terence Herman, Jinming Yu, Min Li","doi":"10.21037/APC.2019.03.02","DOIUrl":"https://doi.org/10.21037/APC.2019.03.02","url":null,"abstract":"Pancreatic cancer (PC) is one of the leading causes of cancer death worldwide. Limited therapeutic options are available. Therefore, how to detect early-stage tumors and how to monitor treatment efficacy and outcomes to allow timely salvage therapies are of crucial importance. Position emission tomography (PET) imaging provides more tumor-associated functional, biochemical and molecular information, without some of the intrinsic limitations of traditional imaging modalities. PET is highlighted as a potential tool to help better understand the mechanism of PC and personalize individual therapeutic regimens. In this review, we outline the available PET imaging modalities and their prospective applications in PC.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75527886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Yin, Xinchun Liu, Tongtai Liu, Yue Fu, Yunpeng Peng, D. Ding, Zipeng Lu, Wen-tao Gao, Junli Wu, K. Jiang, Jishu Wei, Y. Miao
Background: Cholecystectomy is carried out as one of the most extensive abdominal surgery. Patients with a long-term history of cholecystectomy may have an increased risk of pancreatic cancer. However, it’s uncertain whether prior cholecystectomy is associated with the outcome of patients with pancreatic cancer. This study was to demonstrate that prior cholecystectomy may lead to adverse perioperative outcomes in patients with pancreatic adenocarcinoma. Methods: Retrospective study comprising 755 consecutive patients with pathological diagnosis of pancreatic adenocarcinoma in Pancreas Center of the First Affiliated Hospital of Nanjing Medical University (January 2010 to December 2015) was conducted. Demographic details, surgery, tumor stage, pathology and complications were assessed. Patients were divided into NPC (no prior cholecystectomy) group and PC (prior cholecystectomy) group. PC group consist of three subgroups: RC (recent cholecystectomy), LTC (long term cholecystectomy), MTC (medium term cholecystectomy) group. Results: A total of 9.3% (70/755) of the patients underwent prior cholecystectomy, which was significantly more frequent than other operations. The rate is also abnormally higher than Chinese population (1.2%, 31/2,579). Five hundred and fifty-three patients with radical resection were selected. Compared to NPC group, PC group has more progressive tumor with relatively higher level of serum CA19-9 and possibly higher rate of lymph node metastasis. Further analysis showed that RC group had remarkably longer surgery time and more blood loss than NPC group. There was no significant difference of operative time and blood loss between LTC/MTC group and NPC group. Postoperatively, there was no statistical difference between LTC/MTC group and NPC group in complications as POPF (postoperative pancreatic fistula), DGE (delayed gastric emptying), hemorrhage and infection. There was also no notably difference in length of hospital stay these two groups. Conclusions: There is an abnormally high proportion of patients with cholecystectomy history in Chinese patients with pancreatic cancer. Patients with recent cholecystectomy history may have adverse perioperative outcome.
{"title":"Impact of prior cholecystectomy on perioperative outcomes after resection for pancreatic cancer: a single-center, retrospective cohort study in a Chinese population","authors":"L. Yin, Xinchun Liu, Tongtai Liu, Yue Fu, Yunpeng Peng, D. Ding, Zipeng Lu, Wen-tao Gao, Junli Wu, K. Jiang, Jishu Wei, Y. Miao","doi":"10.21037/APC.2019.03.01","DOIUrl":"https://doi.org/10.21037/APC.2019.03.01","url":null,"abstract":"Background: Cholecystectomy is carried out as one of the most extensive abdominal surgery. Patients with a long-term history of cholecystectomy may have an increased risk of pancreatic cancer. However, it’s uncertain whether prior cholecystectomy is associated with the outcome of patients with pancreatic cancer. This study was to demonstrate that prior cholecystectomy may lead to adverse perioperative outcomes in patients with pancreatic adenocarcinoma. Methods: Retrospective study comprising 755 consecutive patients with pathological diagnosis of pancreatic adenocarcinoma in Pancreas Center of the First Affiliated Hospital of Nanjing Medical University (January 2010 to December 2015) was conducted. Demographic details, surgery, tumor stage, pathology and complications were assessed. Patients were divided into NPC (no prior cholecystectomy) group and PC (prior cholecystectomy) group. PC group consist of three subgroups: RC (recent cholecystectomy), LTC (long term cholecystectomy), MTC (medium term cholecystectomy) group. Results: A total of 9.3% (70/755) of the patients underwent prior cholecystectomy, which was significantly more frequent than other operations. The rate is also abnormally higher than Chinese population (1.2%, 31/2,579). Five hundred and fifty-three patients with radical resection were selected. Compared to NPC group, PC group has more progressive tumor with relatively higher level of serum CA19-9 and possibly higher rate of lymph node metastasis. Further analysis showed that RC group had remarkably longer surgery time and more blood loss than NPC group. There was no significant difference of operative time and blood loss between LTC/MTC group and NPC group. Postoperatively, there was no statistical difference between LTC/MTC group and NPC group in complications as POPF (postoperative pancreatic fistula), DGE (delayed gastric emptying), hemorrhage and infection. There was also no notably difference in length of hospital stay these two groups. Conclusions: There is an abnormally high proportion of patients with cholecystectomy history in Chinese patients with pancreatic cancer. Patients with recent cholecystectomy history may have adverse perioperative outcome.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90387294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-01Epub Date: 2019-03-11DOI: 10.21037/apc.2019.02.01
Noah S Rozich, Caitlin E Jones, Katherine T Morris
The objective of this article is to review the available literature examining the impact of malnutrition, frailty, and sarcopenia on surgical morbidity among pancreatic cancer patients. We examine definitions used to diagnose and quantify these conditions and review the differences between them with regards to preoperative assessment and postoperative outcomes. The most relevant scoring systems are summarized. Lastly, we summarize current knowledge regarding effectiveness of specific interventions aimed at malnutrition, frailty, and sarcopenia for patients undergoing pancreatic cancer surgery.
{"title":"Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon.","authors":"Noah S Rozich, Caitlin E Jones, Katherine T Morris","doi":"10.21037/apc.2019.02.01","DOIUrl":"https://doi.org/10.21037/apc.2019.02.01","url":null,"abstract":"<p><p>The objective of this article is to review the available literature examining the impact of malnutrition, frailty, and sarcopenia on surgical morbidity among pancreatic cancer patients. We examine definitions used to diagnose and quantify these conditions and review the differences between them with regards to preoperative assessment and postoperative outcomes. The most relevant scoring systems are summarized. Lastly, we summarize current knowledge regarding effectiveness of specific interventions aimed at malnutrition, frailty, and sarcopenia for patients undergoing pancreatic cancer surgery.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2019.02.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25345116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gastrointestinal (GI) cancer refers to the group of cancers that affect the digestive system. This includes cancers of the oesophagus, stomach, liver, pancreas, gallbladder and biliary tract, small intestine, colon, rectum and anus. GI cancers are regarded as a highly virulent neoplasm with both high morbidity and mortality. Collectively, they are a major cause of morbidity and mortality worldwide (1). Over the past half century, modern radiation therapy has been established and slowly evolved to treat different kinds of GI cancers. However, challenges remain in giving accurate and safe radiation delivery.
{"title":"Eugene J. Koay: translating promising new radiation technologies to patients with gastrointestinal cancers","authors":"Brad Li","doi":"10.21037/apc.2018.12.01","DOIUrl":"https://doi.org/10.21037/apc.2018.12.01","url":null,"abstract":"Gastrointestinal (GI) cancer refers to the group of cancers that affect the digestive system. This includes cancers of the oesophagus, stomach, liver, pancreas, gallbladder and biliary tract, small intestine, colon, rectum and anus. GI cancers are regarded as a highly virulent neoplasm with both high morbidity and mortality. Collectively, they are a major cause of morbidity and mortality worldwide (1). Over the past half century, modern radiation therapy has been established and slowly evolved to treat different kinds of GI cancers. However, challenges remain in giving accurate and safe radiation delivery.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79022932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-01-16DOI: 10.21037/apc.2018.12.02
Patrick W Underwood, Michael H Gerber, Steven J Hughes
Minimally invasive approaches to abdominal surgical procedures have provided superior outcomes when compared to the open approach and thus have become the standard of care. However, minimally invasive pancreatoduodenectomy (MIPD) presents unique difficulties for both laparoscopic and robotic platforms and remains controversial. Ongoing concerns continue about the minimally invasive approach creating meaningful benefit when system-wide data may suggest MIPD results in increased morbidity and mortality during the learning curve. This treatise explores the current state of MIPD, reviewing the volume and quality of data that supports benefit while contrasting the benefits to the unique challenges associated with MIPD that may lead to unacceptable rates of complications and death. We conclude that in a handful of centers, MIPD confers an iterative but not transformative benefit. Significant barriers to the wide-spread acceptance of MIPD are apparent and persist, including: lack of high level data confirming clinical benefit, well defined patient selection criteria, formal education programs that address challenges of the learning curve, and ultimately value.
{"title":"Pitfalls of minimally invasive pancreatoduodenectomy.","authors":"Patrick W Underwood, Michael H Gerber, Steven J Hughes","doi":"10.21037/apc.2018.12.02","DOIUrl":"https://doi.org/10.21037/apc.2018.12.02","url":null,"abstract":"<p><p>Minimally invasive approaches to abdominal surgical procedures have provided superior outcomes when compared to the open approach and thus have become the standard of care. However, minimally invasive pancreatoduodenectomy (MIPD) presents unique difficulties for both laparoscopic and robotic platforms and remains controversial. Ongoing concerns continue about the minimally invasive approach creating meaningful benefit when system-wide data may suggest MIPD results in increased morbidity and mortality during the learning curve. This treatise explores the current state of MIPD, reviewing the volume and quality of data that supports benefit while contrasting the benefits to the unique challenges associated with MIPD that may lead to unacceptable rates of complications and death. We conclude that in a handful of centers, MIPD confers an iterative but not transformative benefit. Significant barriers to the wide-spread acceptance of MIPD are apparent and persist, including: lack of high level data confirming clinical benefit, well defined patient selection criteria, formal education programs that address challenges of the learning curve, and ultimately value.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.12.02","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37641522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01Epub Date: 2018-12-06DOI: 10.21037/apc.2018.11.01
Lei Zheng
Pancreatic cancer is resistant to the immunotherapy. This resistance is caused by any of the four immune "defects" that occur in pancreatic cancer, including lack of "high quality" T cells, stromal barriers to T cells getting access to tumor cells, immunosuppressive cells such as M2 macrophages, myeloid derivative suppressor cells, and T regulatory cells, in the tumor microenvironment of pancreatic cancer. One or more defects may occur in an individual pancreatic cancer. To overcome the resistance to the immunotherapy such as immune checkpoint inhibitors, a rational combination of agents that target multiple immune defects is highly demanded.
{"title":"Immune defects in pancreatic cancer.","authors":"Lei Zheng","doi":"10.21037/apc.2018.11.01","DOIUrl":"https://doi.org/10.21037/apc.2018.11.01","url":null,"abstract":"Pancreatic cancer is resistant to the immunotherapy. This resistance is caused by any of the four immune \"defects\" that occur in pancreatic cancer, including lack of \"high quality\" T cells, stromal barriers to T cells getting access to tumor cells, immunosuppressive cells such as M2 macrophages, myeloid derivative suppressor cells, and T regulatory cells, in the tumor microenvironment of pancreatic cancer. One or more defects may occur in an individual pancreatic cancer. To overcome the resistance to the immunotherapy such as immune checkpoint inhibitors, a rational combination of agents that target multiple immune defects is highly demanded.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.11.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36838418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There are over 20 different types of cystic lesions of the pancreas, most of which are benign (1). The four most common pancreatic cysts with neoplastic potential are serous cystadenoma (SCA), solid pseudopapillary neoplasm (SPN), mucinous cystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN).
{"title":"Pancreatic cystic neoplasms: usually incidental, rarely incident","authors":"E. Duell","doi":"10.21037/APC.2018.09.04","DOIUrl":"https://doi.org/10.21037/APC.2018.09.04","url":null,"abstract":"There are over 20 different types of cystic lesions of the pancreas, most of which are benign (1). The four most common pancreatic cysts with neoplastic potential are serous cystadenoma (SCA), solid pseudopapillary neoplasm (SPN), mucinous cystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN).","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88507346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Si, T. Hieken, A. Degnim, Zhiying Yang, H. Tan, Yongliang Sun, Liguo Liu, Wenying Zhou, Jia Huang
Background: The FOLFIRINOX regimen recently became the new standard of care for patients with advanced pancreatic cancer. However, FOLFIRINOX hasn’t been widely used in China as the hesitance of oncologists to use FOLFIRINOX due to the toxicity of the regimen and the presumption that Chinese patients could not tolerate FOLFIRINOX. Methods: We retrospectively analyzed the clinical data of ten patients with pancreatic cancer who received the FOLFIRINOX regimen from July 2016 to July 2018. The two woman and eight men enrolled were aged 29 to 76 years. Three, three, and four patients were diagnosed with borderline resectable pancreatic cancer (BRPC), liver-metastatic pancreatic cancer (LMPC), and recurrent pancreatic cancer (RPC), respectively. Seven and three patients received a full or 80% initial dose, according to their Eastern Cooperative Oncology Group performance status. Results: One of the seven patients was administered an 80% dose after the second cycle because of febrile neutropenia (grade >3). The most common adverse event was neutropenia (grade 2). Four patients with BRPC or LMPC successfully underwent surgical resection. Two patients with LMPC achieved partial remission (PR). The levels of the serum carbohydrate antigen 19-9 of three patients with RPC significantly decreased (>60%). Conclusions: The FOLFIRINOX regimen is effective and is tolerated by certain Chinese patients with advanced pancreatic cancer. The dose of the FOLFIRINOX regimen should be individually adjusted to reduce toxicity.
{"title":"Case analysis of pancreatic cancer treated with FOLFIRINOX in China","authors":"S. Si, T. Hieken, A. Degnim, Zhiying Yang, H. Tan, Yongliang Sun, Liguo Liu, Wenying Zhou, Jia Huang","doi":"10.21037/APC.2018.09.01","DOIUrl":"https://doi.org/10.21037/APC.2018.09.01","url":null,"abstract":"Background: The FOLFIRINOX regimen recently became the new standard of care for patients with advanced pancreatic cancer. However, FOLFIRINOX hasn’t been widely used in China as the hesitance of oncologists to use FOLFIRINOX due to the toxicity of the regimen and the presumption that Chinese patients could not tolerate FOLFIRINOX. \u0000 Methods: We retrospectively analyzed the clinical data of ten patients with pancreatic cancer who received the FOLFIRINOX regimen from July 2016 to July 2018. The two woman and eight men enrolled were aged 29 to 76 years. Three, three, and four patients were diagnosed with borderline resectable pancreatic cancer (BRPC), liver-metastatic pancreatic cancer (LMPC), and recurrent pancreatic cancer (RPC), respectively. Seven and three patients received a full or 80% initial dose, according to their Eastern Cooperative Oncology Group performance status. \u0000 Results: One of the seven patients was administered an 80% dose after the second cycle because of febrile neutropenia (grade >3). The most common adverse event was neutropenia (grade 2). Four patients with BRPC or LMPC successfully underwent surgical resection. Two patients with LMPC achieved partial remission (PR). The levels of the serum carbohydrate antigen 19-9 of three patients with RPC significantly decreased (>60%). \u0000 Conclusions: The FOLFIRINOX regimen is effective and is tolerated by certain Chinese patients with advanced pancreatic cancer. The dose of the FOLFIRINOX regimen should be individually adjusted to reduce toxicity.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91387022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-01Epub Date: 2018-10-10DOI: 10.21037/apc.2018.09.03
Gregory B Lesinski
{"title":"Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells.","authors":"Gregory B Lesinski","doi":"10.21037/apc.2018.09.03","DOIUrl":"https://doi.org/10.21037/apc.2018.09.03","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.09.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38047564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
New literature published in Gut has shown that combined treatment of anti-BAG3 mAb and anti-PD-1 mAb in pancreatic cancer can eliminate tumor-associated macrophages (TAMs), increase tumor infiltrating CD8+ T cells and result in tumor growth suppression (1). These findings highlight the potential of BAG3 (Bcl-2-associated athanogene 3) as a therapeutic target in conjunction with immune checkpoint blockade in the treatment of pancreatic cancer.
{"title":"Depletion of tumor associated macrophages by anti-BAG3 treatment complements PD-1 blockade in pancreatic cancer","authors":"Yi Sun, R. Torphy, Yuwen Zhu","doi":"10.21037/APC.2018.10.01","DOIUrl":"https://doi.org/10.21037/APC.2018.10.01","url":null,"abstract":"New literature published in Gut has shown that combined treatment of anti-BAG3 mAb and anti-PD-1 mAb in pancreatic cancer can eliminate tumor-associated macrophages (TAMs), increase tumor infiltrating CD8+ T cells and result in tumor growth suppression (1). These findings highlight the potential of BAG3 (Bcl-2-associated athanogene 3) as a therapeutic target in conjunction with immune checkpoint blockade in the treatment of pancreatic cancer.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81726680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：